Nutrient composition

FIELD: food industry.

SUBSTANCE: inventions group relates to a nutrient composition for preterm infants with very low body weight at birth: with weight equal to 1500 g or less. The composition contains 26-38 g/l of a source of hydrolysed whey protein with 8-20 hydrolysis degree free of allergenic substances, 37-46 g/l of a source of fats, whereof 20-40% are triglycerides with an average length of molecular chain, having a value of n6:n3 ratio 6-12, and 50-100 g/l of a carbohydrates source, the composition containing 3.2-4.0 g of protein per 100 kcal. Application of the source of hydrolysed whey protein with 8-20 hydrolysis degree free of allergenic substances in an amount corresponding to a protein content from 3.2 to 4.0 g of protein per 100 kcal in the process of production of the composition for stimulation of growth with infants with very low body weight at birth with weight equal to 1500 g or less. Application of the source of hydrolysed whey protein with 8-20 hydrolysis degree free of allergenic substances in an amount corresponding to a protein content from 3.2 to 4.0 g of protein per 100 kcal in the process of production of the medical agent for stimulation of growth with infants with very low body weight at birth with weight equal to 1500 g or less.

EFFECT: inventions group allows to stimulate growth of infants with very low body weight at birth.

17 cl, 2 tbl, 2 ex

 

The technical field to which the invention relates.

The present invention relates to nutritional compositions for preterm infants with very low birth weight at birth and that meets the nutritional requirements of such infants.

The level of technology

Breast milk is recommended for all infants. However, in some cases, in particular in the case of premature infants, breastfeeding may for medical reasons to be insufficient or unsuccessful or impractical, or even impossible. For such cases designed mixture for infants.

Premature babies are babies born before completion of 37 weeks of pregnancy. These babies usually demonstrate functional underdevelopment, which is expressed even more clearly, the higher the degree of prematurity. This underdevelopment manifests itself in a variety of ways. For example, premature baby can have the underdevelopment of the gastrointestinal tract, manifested, in particular, in regard to its ability to absorb nutrients and sophistication and efficiency of intestinal barrier function.

Have been proposed various techniques to improve intestinal barrier function or condition of the gastrointestinal tract in premature infants. For example, in U.S. patent 6132710 in CE is s prevention caused by infection of the lesions and inflammation of the tissue of the mucous membranes preterm children were administered purified strains of lactic acid bacteria Lactobacillus salivarius and Lactobacillus plantarum, using, in particular, nasogastric introduction to prevent tissue lesions of the gastrointestinal tract and reduce the risk of necrotizing enterocolitis of newborn.

In addition, premature baby may also suffer from a limited ability to metabolize certain amino acids such as phenylalanine, which can lead to serious amino acid imbalance if your protein intake exceeds the ability to splitting. On the other hand, the presence of essential amino acids can be a limiting factor in protein synthesis and, consequently, growth. Indeed, some amino acids such as tyrosine and cysteine, which are not essential for a child born in period for a premature baby can be invaluable.

Recent advances in medical science make possible the survival of more and more premature babies. Currently, it is believed that the minimum make possible the survival of the body weight at birth is between 500 and 600, Such infants are faced with specific problems associated with their low weight and with a degree of underdevelopment.

If such infants with very low birth weight at birth would remain in the uterus during the normal period of human gestation, besides what about the achievement of normal physiological development, they would at the same time was rapidly increased in size. It would be desirable to provide such infants adapted nutrition, contributing to the achievement of a growth rate similar to that which they had inside the womb. However, the need to avoid stress underdeveloped metabolic abilities and excretory functions overloaded attaches special importance to the selection of the quality and quantity of protein in the development of formulations of nutrition for babies with very low birth weight at birth.

Disclosure of inventions

The present invention provides a nutritional composition for infants with very low birth weight at birth, which contains 26-38 g/l source free from allergenic substances hydrolyzed whey protein with a degree of hydrolysis 8-20, 37-46 g/l of a source of fat, of which 20-40% are triglycerides with an average length of the molecular chain, and which has a ratio n6:n3 6-12, and 50-100 g/l of a source of carbohydrates, a composition that contains a 3.2-4.0 grams of protein per 100 kcal.

The invention extends to the use of the source free from allergenic substances hydrolyzed whey protein with a degree of hydrolysis 8-20 in an amount corresponding to the protein content of from 3.2 to 4.0 g of protein per 100 kcal, in the production of nutritious HDMI is tion or drugs to stimulate growth in infants with very low birth weight at birth.

In addition, the invention extends to a method of stimulating the growth of the needy in infants with very low birth weight at birth through the introduction of the baby therapeutic amount of a nutritional composition containing a source of free from allergenic substances whey protein with a degree of hydrolysis 8-20 in an amount corresponding to the protein content of from 3.2 to 4.0 g of protein per 100 kcal.

Information that reveals the essence of the invention

In the present description, the following terms have the following meanings:

"a child with very low weight at birth or VLBW infant" means an infant with a body weight at birth of less than 1500 g;

"degree of hydrolysis" (DH) denotes the percentage of nitrogen in the form of a free alpha-amino nitrogen in relation to the total nitrogen measured by the TNBS method described by Adler-Nissen and others in the "Determination of the Degree of Hydrolysis of Food Protein Hydrolysates by Trinitrobenzenesulfonic acid (J.Agric. Food Chem., 1979, vol.27, n.6, p.1256-1262). It is an indicator of the extent to which protein was obtained;

"fostering growth in VLBW-baby" denotes promote VLBW-baby growth rate comparable to demonstrate the fetus of the same gestational age in the mother's womb.

All references to percentages, unless otherwise represented by mass percentage.

Links to content is of certain nutrients in grams per liter relate to nutritional composition, ready-to-use. In the case of powdered products this refers to the powder prepared according to the instructions.

Nutritional composition according to the invention contains a source of free from allergenic substances hydrolyzed whey protein with the size of 8-20 DH, more preferably 9-16. Particularly preferred degree of hydrolysis equal to 14. Whey protein can be hydrolyzed by any suitable, well known in this field by the way, for example as described in European patent No. 0322589, the content of which is presented here by reference. Found that if used as source material the serum fraction is essentially free of lactose, protein undergoes significantly less blocking of lysine during the hydrolysis and subsequent heat treatment. This makes it possible to decrease the degree of blocking of lysine from about 15 wt.% total lysine to less than about 10 wt.% lysine, for example, about 7 wt.% blocking of lysine, which greatly improves the nutritional quality of the protein source.

Source of whey protein can be acid whey, sweet whey, whey protein, or mixtures thereof. However, it is preferable that the source of protein was based on whey protein or modified sweet savoro the ke. Sweet whey is a readily available by-product of the manufacture of cheese and is often used in the production of mixtures based on cow's milk. However, sweet whey includes a component called casein-glycol-macropeptide (CGMP), which has undesirable high content of threonine and insufficient - tryptophan. The destruction of CGMP from sweet whey leads to a protein with the closest to breast milk content of threonine. This modified sweet whey can then be supplemented by those amino acids whose content therein is low (mainly histidine and arginine). Method of removing CGMP from sweet whey is described in EP 0880902.

If the protein source is used, a modified sweet whey or whey protein isolate, preferably it is supplemented by a free arginine in an amount of from 0.1 to 2 wt.% protein and/or free histidine in an amount of from 0.1 to 3 wt.% protein.

Below is an example of amino acid profile that is appropriate for the nutritional composition according to the present invention.

Table
Amino acid (g / 100 g protein)Number
Isoleucine 5,1
Leucine12,1
Lysine9,1
Methionine2,2
Cystine2,6
Phenylalanine3,7
Tyrosine3,1
Threonine5,6
Tryptophan2,1
Valine5,2
Arginine3,5
Histidine3,6
Alanya5,0
Aspartic acid11,0
Glutamic acid15,8
Glycine2,2
Proline4,6
Serine4,8

Nutritional composition according to the present invention contains from 3.2 to 4.0 g free from all gennych substances hydrolyzed whey protein per 100 kcal, more preferably from 3.4 to 3.7 g/100 kcal. Particularly preferred protein is 3.6 g/100 kcal.

Nutritional composition according to the present invention contains from 37 to 46 g/l of a source of fat, of which 20-40% is a triglyceride with a molecular chain of medium length (MCT). Preferably the fat content ranges from 39 to 43 g/L. the Preferred content of MCT is between 25 and 35%. Forming lipids, the fat source may be any suitable fat or mixture of fats. Especially suitable are vegetable fats, for example, soybean oil, palm oil, coconut oil, safflower oil, sunflower oil, corn oil, canola oil, etc. with a Suitable source of MCT is fractionated coconut oil.

However, the main difference between fat milk and these triglycerides of vegetable origin lies in the fact that most of the triglycerides of plant origin are the remains of an unsaturated fatty acid at the Sn2 position, whereas triglycerides breast milk is the most common in the Sn2 position residue is a residue of a saturated fatty palmitic acid. It is shown that residues of fatty acids are better absorbed from the Sn2 position and that this is especially important for the absorption of palmitic acid nadooshan the children. So is the preferred inclusion in the source of fat is from 5 to 20% of a structured lipid, in which triglycerides were subjected to enzymatic or other interesterification, so that traces of palmitic acid was present mainly in the Sn2 position. One example of a suitable structured lipid is a lipid offered for sale by the company of Lipid Nutrition, a subsidiary of Loders Croklaan, under the trademark Betapol®. Preferably at least 40% of the palmitic acid residues are a source of fat in the Sn2 position, more preferably between 45 and 55%.

The ratio of n6:n3 used in the composition according to the present invention the source of fat is 6-12, more preferably 7-10. Especially preferred ratio n6:n3 is equal to 9:1. If desired, the fat mixture can be supplemented with long-chain polyunsaturated fatty acids, preferably selected from fungal and algal biomass, such as arachidonic and docosahexaenoic acids, offer Martek Inc under the trade names Arasco® and Dhasco®, respectively, up to 3% of the total number of source of fat. The preferred proportion of arachidonic acid and docosahexaenoic acid is about 2:1.

Nutritional composition contains 50 to 100 g/l, predpochtite the flax 70-90 g/l of a source of carbohydrates. Can be any suitable carbohydrates, such as lactose, dried corn syrup, maltodextrins and mixtures thereof. Preferred are mixtures of lactose and maltodextrin, preferably in the range from 20% lactose and 80% maltodextrin to 60% lactose and 40% maltodextrin. Particularly preferred mixture is represented by a ratio of 40% lactose and 60% maltodextrin.

In the nutritional composition may include suitable vitamins and minerals in amounts that meet the relevant standards, with particular attention to the content of sodium, potassium, chloride, calcium, phosphorus, iron, selenium, zinc, vitamin a and vitamin E. for Example, the composition may contain per 100 kcal: sodium 50 to 70 mg (preferably 55-65 mg), potassium 120 to 150 mg (preferably 130-140 mg), chloride 80 to 110 mg (preferably 90-100 mg), calcium from 130 to 170 mg (preferably 140-160 mg), phosphorus from 80 to 105 mg (preferably 85-95 mg), iron from 1.6 to 2.5 mg (preferably 1.7 to 2.0 mg), selenium from 2.0 to 6.0 μg (preferably 3,0-5,0 g), zinc from 1.1 to 1.6 mg (preferably 1.4 to 1.6 mg), from 800 to 1200 IU of vitamin A (preferably 900-1100 ME) and from 3 to 9 IU of vitamin E (preferably 5-7 ME).

The nutritional composition may also contain nucleotides in the following quantities per 100 kcal: UMP 1.0 to 4.0 mg, SMR 1.5 to 5.5 mg, AMP 0.3 to 1.5 mg and GMP of 0.1-0.5 mg

Nourishing the composition may be prepared in any suitable way. For example, it may be prepared by mixing the hydrolyzed whey protein, a carbohydrate source and the fat source in appropriate proportions. If using, at this stage can be included emulsifiers. At this stage, can also be added vitamins and minerals, but usually, in order to avoid thermal decomposition, they are added later. Before mixing in the source of fat can be dissolved any lipophilic vitamins, emulsifiers and the like, Then, to obtain a liquid mixture can be mixed with water, preferably water processed by reverse osmosis. Suitable for facilitating the dispersion of the ingredients the water temperature ranges from about 50°to about 80°C. To obtain a liquid mixture can be used a commercially available thinners. Then the liquid mixture is homogenized, for example, in two stages.

Then to reduce the bacterial load of the liquid mixture may be subjected to a heat treatment by rapid heating to a temperature in the range from about 80°to about 150°C for a time from about 5 seconds to about 5 minutes, for example. This can be accomplished by injection of steam, autoclave or by using a heat exchanger, for example a plate heat exchanger.

Then, the liquid mixture may be cooled to a temperature of from the eye is about 60°to about 85°C, for example, an instant cooling. Then the liquid mixture may be homogenized, for example, in two stages: at a pressure of from about 10 MPa to about 30 MPa in the first stage and from about 2 MPa to about 10 MPa in the second stage. Next gomogenizirovannogo mixture may be further cooled to add any heat sensitive components, such as vitamins and minerals. At this stage in the homogenized mixture is conveniently governed by the pH and solids content.

If you want obtaining powdered nutritional composition, gomogenizirovannogo mixture comes to a suitable drying device such as a spray dryer or the installation of freeze drying, and converted into powder. The powder should have a moisture content less than about 5 wt.%.

If it is desired to produce liquid compositions, gomogenizirovannogo the mixture is placed in suitable containers, preferably under aseptic conditions by heating the homogenized mixture (for example, to a temperature of from about 75 to 85°C), and then in gomogenizirovannogo mixture injected steam to raise the temperature to a value of from about 140 to 160°C, for example, up to about 150°C. Then, the liquid mixture may be cooled, for example, instant cooling, to a temperature of from about 75°to about 85°C. After kagomes can be re-homogenized, next cooled to a temperature close to room temperature and filled into containers. A suitable device for the aseptic filling of this kind offered in the sale. The liquid composition may be in the form of ready-feeding composition having a solids content from about 10 to about 14 wt.%, or may be represented in the form of a concentrate with a regular solids content from about 20 to about 26 wt.%.

In another aspect the present invention provides a method of promoting the growth we need in VLBW-infants through the introduction of the baby therapeutic amount of a nutritional composition containing a source of free from allergenic substances whey protein with a degree of hydrolysis 8-20 in an amount corresponding to the content of Beja from 3.2 to 4.0 g of protein per 100 kcal.

The needs of premature babies in proteins is not quite clearly defined. The American Academy of Pediatrics (American Academy of Pediatrics) recommends that the reception of protein in quantities of from 2.9 to 3.3 g/100 kcal [AAPCON, 2003], while the European society of paediatric gastroenterology and nutrition (recommends acceptance 2.2-3.1 g/100 kcal [ESPGAN-CON, 1987A]. However, the recommended protein food rations (RDPI) relate to babies born after a gestational age ≥26 weeks and have weight ≥800 g but not to a less Mature or less mladé the Indians, the needs which can be higher. RDPI is also based on the needs associated with normal growth, but do not take into account the conditions necessary for the achievement of infant growth rates, comparable to those that would have occurred in the womb, which may be crucial for these children. Actually RDPI may systematically underestimate the "true" protein requirements such high risk VLBW babies.

The amount of added nutrient composition will vary depending on the degree of goosenest or growth of the baby, but provided that she is the only source of food the child can either be supplied depending on the query, or if the baby itself unable to control the consumption, in accordance with the calculations of a qualified specialist in the field of health, has custody of VLBW infant.

Further, the invention is illustrated by the following examples.

Example 1

An example of the nutritional composition according to the present invention consists in the following:

Table
The density of calories (kcal/100 ml)80
Protein (g/100 kcal) 3,6
ProteinFree from allergenic substances hydrolyzed whey protein
DH14
1,4% (protein) of free arginine
1,9% (protein) free histidine
Fats (g/100 kcal)5,2
of which:
MCT30%
Preterition palm oil11% (56% palmitic acid in the Sn2 position)
ARA0,6%
DHA0,3%
n6:n39:1
ARA: DHA2:1
Carbohydrates (g/100 kcal)9,9
Lactose / maltodextrin40/60
Electrolytes and minerals per 100 kcal
Na (mg) 64
K (mg)136
CL (mg)95
CA (mg)150
P(mg)88
CA/P1,7
Mg (mg)10
MP (g)7,0
Vitamins and minerals per 100 kcal
(MB)1000
D (ME)150
E(IU)6,0
K1 (g)8,0
C (mg)30
B1 (mg)0,2
B2 (mg)0,3
Niacin (mg)4,0
B6 (mg)0,2
Folic acid (µg)70
Pantothenic acid (mg) 1,4
B12 (µg)0,25
Biotin (µg)5,0
Choline (mg)15
Inositol (mg)6,5
Taurine (mg)8,0
Carnitine (mg)2,0
Fe (mg)1,8
I (g)35
C (mg)0,15
Zn (mg)1,5
Se (µg)4,0
Nucleotides per 100 kcal
UMP (mg)3,0
SMR (mg)4,6
AMP (mg)0,5
GMP (mg)0,3

Example 2

This example compares the effect of the nutritional composition according to the present invention, used for a group of premature infants as a sole source of p is Tania, to effect control of nutrient composition on indicators such as the absorption of protein, the state of metabolism and growth. The table below presents the composition of mixtures for infants.

Table 1. The composition of the studied mixtures (/100 kcal) *
RecipeControlExperimental
The density of calories (kcal/100 ml)8080
Protein (g)3,03,6
Characterization of proteinhydrolyzed whey protein
Fat (g)5,25,2
MCT (%)2530
Carbohydrates (g)10,59,9
Lactose / maltodextrin40/6020/80
Minerals
5564
Potassium (mg)120136
Chloride (mg)8595
Calcium (mg)131131
Phosphorus (mg)7575
Iron (mg)1,50
Copper (mg)0,10,1
Zinc (mg)1,21,2

Recipe mixtures differed primarily on protein content (3,0 against 3.6 g/100 kcal). Other differences are noted in the content of carbohydrates (against 9,9 10,5 g), electrolytes (see above), vitamin a (350 to 500 ME) and iron (1.5 mg vs. 0).

The study had a prospective, double-blind, randomized and cross-cutting nature, in which each child received a mixture of both formulations. The sequence of feeding formulations were asked proportional, random. Infants randomized into group a, first received the experimental protein recipe, as a control protein recipe - second. Infants randomized to the group In the first received control protein formulation, and then the experimental protein recipe.

Infants were recruited from two centers: the Special Care Baby Unit, Royal Victoria Infirmary, Newcastle-upon-Tyne, UK, and Service Universitaire de Neonatologie Liege, Liege, Belgium. In each of the centres in the study received the approval of the local Ethical Committee. From the parents/guardian(s) has been consented to in writing on the basis of full information.

Relevant selection criteria in the study were considered preterm infants (≤1500 g, gestational age ≤32 weeks). Gestational age was determined using the data obtained from the mothers, and the results of intrauterine ultrasound examination. Were enlisted only those who were clinically stable and were completely on enteral nutrition (≥130 ml/kg/day). In need of oxygen therapy infants were considered to meet the selection criteria, however, they were excluded if oxygen therapy was required of them at the time of receipt of the results of the first tests of nutrient balance. Infants treated with diuretics or steroids in the test were not included.

When determined appropriate, the child was asked to meet him to the doctor. Then spoke to the guardian(s), giving the were explained the study and provided their written statement. After obtaining written consent based on full information, the child was entered into the list of participants in the study. Then appeared the main anthropometric and biochemical parameters and the baby was randomizable in one of two study groups.

During the first test of the balance of the infants were mainly fed by continuous nasogastric infusion. When the second balance test infants received food bolus dosing or orally in accordance with the requests.

Each test series was designed to last for one week. After establishing a tolerance for ≥48 hours enteral introduction of the first operating recipe in the volume of ≥135 ml/kg/day was carried out anthropometry, were taken the sample of blood and began the first study of balance. At the end of the first studies of balance again starred anthropometric data and selected a second sample of blood. Then he asked the second study the recipe and the process was repeated. At the end of learning a second balance the study was completed.

In the first study of the daily balance was determined with the introduction of nutrients researched recipes and maintained at 135-150 ml/kg/day. During the second study balance it was not always possible, pascalc is some infants received power according to their requests. Body weight, serum urea, serum electrolytes, the pH value of the blood and excess reason was measured at the beginning of the study, at the end of the first study of balance and at the end of the second collection of data on balance. At the end of each study balance was measured concentrations of retinol binding protein (RBP) and serum transferrin.

Sampling of blood was performed in the morning and time was calculated in such a way as to coincide with the end of each feeding cycle (continuous)or run directly before feeding. Immediately carried out the analysis for the determination of blood gases. Also immediately separated plasma. One aliquot of the sample was sent to the Central laboratory for analysis of the electrolyte, urea nitrogen, total protein and albumin. The second aliquot was stored at -30°C and later went for analyses on transferrin and RBP.

Anthropometric data were removed as described previously [Cooke, a]. Electrolytes, urea nitrogen, total protein and albumin were analyzed using standard laboratory techniques. Transferrin was determined immunoturbidimetric with application kit "Tina-quant transferrin Kit" (Roche N° 1 931 628, Switzerland) [Kreutzer, 1976; Lievens, 1994]. The level of RBP was measured immunoturbidimetric using rabbit antisyware to connecting ethanol protein [Gulamali, 1985] is used as the calibration standard human "N Protein Standard SL (Dade Behring, Germany). Determination was performed using an analyzer "BM/Hitachi 917 Analyser" (Roche, Switzerland).

The collection of data on the nutrient balance was performed as described previously [Cooke, a]. Capacity formulation were weighed before and after each feeding, the difference in weight was used to calculate the value of the introduction of the recipe. In addition, the power supply from the tanks was carried out until complete devastation, the magnitude of the difference in weight between a full and empty containers were used to cross-check the accuracy of determination of total mass entering portions of food. Spilled food were collected on pre-weighed diapers, wrap around the baby; the difference in mass between clean and "soiled" diaper was used to calculate losses.

Urine and feces (girls) and feces (boys) was about half pans of Pyrex placed under the infant. The urine of boys gathered in the package for collection of urine. Urine, faeces and mix for power was analyzed for nutrient content in the centres Samuel J Fomon Infant Nutrition Unit of the University of Iowa, Iowa, USA and Service Universitaire de Neonatologie Liege, Liege, Belgium. Nitrogen was determined by the decomposition of microprobe by Kjeldahl method, followed by modified microdiffusion and what Alison [Fomon, 1973].

Calcium, magnesium, iron, copper and zinc were determined by atomic absorption spectrophotometry (Perkin-Elmer, model 560). Fat was determined using a modification of the method of Van de Kamer and others [Van de Kamer, 1949], phosphorus - using described Leloir and Cardini phosphoramidates [Leloir, 1957].

The volume of injection was calculated by dividing the difference between the weight per unit weight of the formulation. The magnitude of nutrient input was calculated from the volume flow and content of the formulation. Excretion of feces was calculated by weight and the content of stool excretion - the scope and content of the urine. The absorption values were calculated by subtracting the amount of stool from the magnitude of the hold - subtraction value of urinary tract absorption.

While collecting data on the balance of care for the child was provided by nurses, is responsible only for the individual concerned of the baby. These nurses are specially trained in the skills of caring for premature children and execution of data collection for the balance. General supervision of infants was carried out under the supervision of a responsible physician. All regular treatments were performed, as shown.

Determination of sample size was correlated with the retention of nitrogen and based on the standard deviation of 20 mg/kg/day with a credible deviation at 30 mg/kg/day in statistical the power of the study, equal to 0.80, and the rate of alpha equal to 0.05. The center-to-center assumption of variation was evaluated in such a way that fully complete the study have 16 babies.

Data were analyzed in order processing using analysis of variance (ANOVA). The results were considered significant at p<0,05.

Were studied eighteen infants (9 girls and 9 boys). Mean (±SD) weight at birth and gestational age was 1226±204 g and 29.5±1.5 weeks. During the study, none of the infants had not received supplemental oxygen or medicines. Nine infants first received experimental recipe and 9 babies - control recipe.

At the entrance to the study of postnatal age (18±8<25±9 days; p<0,05), but not corrected age (229±5 vs. 229±6 days), body weight (1473±262 against 1470±197 g), parieto-heel length (40±2.7, against 40±1.7 cm) or occipital-frontal circumference (29±2,2 vs. 29±1.6 cm) infants who received first experimental recipe, accordingly differed from similar indicators infants receiving first control compounding.

Performed study of thirty-six balances in 18 infants. The absorption and retention of nitrogen was found to be a linear function of the introduction. Introduction (743±71>604±35 mg/kg/day, p<0,001), absorption (624±84>500±49, p<0,001) and retention(514±85> 426±45, p<0.001) in the experimental protein formulations were higher. It was not revealed any differences between the formulations in percentage absorption (83±6 vs. 84±6) or in the percentage of retention (71±6 vs. 70±6).

The results of the residual values of the balance sheet presented in the following Table 2.

td align="center"> 556±354
Table 2
RecipeIntroductionAbsorption% absorptionThe retention% retention
Fats3.6 g6,6±0,65,1±0,877±9
(g/kg/day)3.0 g6,6±0,44,8±0,7*73±11*
Calcium3.6 g181±1785±3246±1783±32 46±14
(mg/kg/day)3.0 g181±1282±3645±1981±3545±19
Phosphorus3.6 g101±1088±1087±5,271±1Z70±11
(mg/kg/day)3.0 g103±691±7,189±4,266±1164±10
Magnesium3.6 g12,6±1,26,0±2,148±155,6±2,045±12
(mg/kg/day)3.0 g11,1±0,8*5,3±1,748±155,0±1,845±15
Zinc3.6 g1819±175574±35831±1831±15
(ág/kg/day)3.0 g1964±137*563±36128±18544±37028±18
Copper3.6 g166±1643±4925±29
(ág/kg/day)3.0 g205±18*83±41*40±19*

Introduction fats had a similar character, but in the case of experimental recipe cloudline was less, while the absorption higher (p<0,05). Although there were reported slight differences in the introduction of magnesium and zinc, any differences between the formulations regarding the balance of calcium, phosphorus, magnesium or zinc were observed. However, the introduction and absorption of copper in the control formulation were higher (p<0,05).

When sampling blood of any differences in the postnatal age were found (33±10 vs 31±7 days for the experimental and control formulations). No real is of the infants were observed development of uremia (urea ≥7.0 mmol) or metabolic acidosis (deficit basis ≥-8,0) [Schwartz, 1979], but the rate of urea in serum was higher when using the experimental formulations (3,5±1,3>2,1±0.8 mmol, p<0,001). There were not observed any differences between the formulations relative to the pH of blood (7,38±0,04 against 7,37±0,04) or excess basis (-1,2±1.7 against -1,4±2.1 mmol/l).

Any differences in creatinine (44±5 vs. 46±12), total protein (44±3 vs. 45±3 g/l), albumin (31±3 vs. 31±3 g/l) or transferrin (20±3 vs. 21±4) were not found, however, RBP was higher in the experimental formulations (12,4±3,3>11,0±2,6; p<0,05). The increase in weight was also higher (average difference of 11±12 g/day; p<0.05)and the effect was more pronounced in boys than in girls.

Consensus recommendations for the introduction of protein for infants weighing at birth <1000 g be ~3.0 g/100 kcal. However, these recommendations assume that the increment of tissue for growth is ~2.3 g/kg/day. Recent data suggests that the need for tissue closer to 2.5 g/kg/day. In the assumption that obligate loss of protein through urine and skin [Snyderman, 1969] are 1.0 g/kg/day and the norm of the relative absorption of 90% of requirements can be closer to 3.6 g/100 kcal.

Existing recommendations relate to needs for normal growth, but in the case of the sick, unstable premature babies need time to establish RDPI. Therefore, m is Udintsev accumulated deficit of nutrients, and less developed than the baby, the higher the degree of deficiency. In this study, the average deficit of protein in the beginning of the study was ~10 g/kg, contributing to increased needs of these high risk infants.

In this study, by increasing the introduction of protein from 3.4 to 5.2 g/kg/day similarly increased absorption and retention. None of the infants were observed for the development of uraemia or metabolic acidosis, nor was there any difference in acid-base status between the experimental and control formulations. At the same time, the growth was better under the assumption that the experimental formulation to better meet the needs of these high risk infants.

The data from this study are essential. There is a problem with potentially adverse impacts of the introduction of high levels of food Beja. Recent recommendations suggest an upper limit of 4 to 4.5 g/kg/day. The data from this study show that the introduction of proteins in quantities of up to 5.2 g/kg/day is not only well tolerated, but also associated with better growth.

1. Application source free from allergenic substances hydrolyzed whey protein with a degree of hydrolysis 8-20 in an amount corresponding to the content b is the left main coronary artery from 3.2 to 4.0 g of protein per 100 kcal, in the production of nutritional compositions for stimulating growth in infants with very low birth weight birth weight equal to or less than 1500

2. The use according to claim 1, in which the degree of protein hydrolysis is 9-16.

3. The use according to claim 1 or 2, wherein a source of whey protein is sweet whey from which has been removed casein-Glyco-macropeptide, or whey protein isolate.

4. The use according to claim 3, in which the composition additionally includes free arginine in an amount of from 0.1 to 2.0 wt.% protein and/or free histidine in an amount of from 0.1 to 3 wt.% protein.

5. The use according to claim 1 or 2, in which the protein content in the nutrient composition ranges from 3.4 to 3.7 g/100 kcal.

6. Application source free from allergenic substances hydrolyzed whey protein with a degree of hydrolysis 8-20 in an amount corresponding to the protein content of from 3.2 to 4.0 g of protein per 100 kcal, in the production of medicines to stimulate growth in infants with very low birth weight birth weight equal to or less than 1500

7. The use according to claim 6, in which the degree of protein hydrolysis is 9-16.

8. The use according to claim 6 or 7, in which the source of whey protein is sweet whey from which has been removed casein-Glyco-macropeptide, or whey protein isolate.

9. Use the group by clause 8, in which the composition additionally includes free arginine in an amount of from 0.1 to 2.0 wt.% protein and/or free histidine in an amount of from 0.1 to 3 wt.% protein.

10. The use according to claim 6 or 7, in which the protein content of the medicinal product ranges from 3.4 to 3.7 g/100 kcal.

11. Nutritional composition for infants with very low birth weight birth weight equal to or less than 1500 g, which contains 26-38 g/l source free from allergenic substances hydrolyzed whey protein with a degree of hydrolysis 8-20, 37-46 g/l of a source of fat, of which 20-40% are triglycerides with an average length of the molecular chain and which has a ratio n6:n3 6-12 and 50-100 g/l of a source of carbohydrates, a composition that contains a 3.2-4.0 g of protein per 100 kcal.

12. The composition according to claim 11, in which the degree of hydrolysis is 9-16.

13. The composition according to claim 11 or 12, in which the source of whey protein is sweet whey from which has been removed casein-Glyco-macropeptide, or whey protein isolate.

14. The composition according to item 12, which further includes the free arginine in an amount of from 0.1 to 2.0 wt.% protein and/or free histidine in an amount of from 0.1 to 3 wt.% protein.

15. The composition according to claim 11 or 12, which contains from 3.4 to 3.7 g of protein per 100 kcal.

16. The composition according to claim 11 or 12, in which the source of fat contains from 25 to 5% of triglycerides with a molecular chain of medium length.

17. The composition according to claim 11 or 12, in which the source of fat contains from 5 to 20% of a structured lipid, in which at least 50% is contained in the structured lipid residues of palmitic acid tarifitsirovana in the Sn2 position.



 

Same patents:

FIELD: medicine.

SUBSTANCE: present invention refers to medicine, namely to therapy and endocrinology, and can be used for glucose level correction by gluconeogenesis optimisation in a body. That is ensured by introduction of a daily dietary intake with a carbohydrate quota reduced to 150-100 g and the content of glucogenic amino acids increased to 20000-40000 mg 2-3 times a week. Said dietary intake is prescribed after intensive physical exercises allowing to lose 2000-3000 kcal/day. Such loads are carried out in the form accessible to a specific person as jogging, swimming, football, volleyball or work in the garden.

EFFECT: method provides a protein-glucogenic diet stimulating gluconeogenesis enzyme development by a liver.

3 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry, particularly to an agent for treating or preventing a peripheral neuropathy. An extract of a family Dioscoreaceae for preventing or treating the peripheral neuropathy recovered by extraction of a of the family Dioscoreaceae with a first extraction solvent selected from the group consisting of water, C1-C4 alcohol and a mixture of water and C1-C4 alcohol. The pharmaceutical composition for preventing or treating the peripheral neuropathy. A food composition for preventing or treating the peripheral neuropathy.

EFFECT: preparations are effective for treating or preventing the peripheral neuropathy.

8 cl, 9 dwg, 1 tbl, 11 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to cardiology and angiologia, and can be used for optimising vascular wall activity in patients with degree I-II arterial hypertension (AH) associating metabolic syndrome (MS) suffered eye vessel thrombosis. That is ensured by introduction of the preparations pioglitazone and amlodipine with underlying an individually prescribed hypocaloric diet and graduated physical exercises. The hypocaloric diet is calculated in kcal by formula: for women of 18-30 years old - (0.0621 × body weight, kg + 2.0357) × 240, of 31-60 years old - (0.342 × body weight, kg + 3.5377) × 240, over 60 years old - (0.0377 × body weight, kg + 2.7545) × 240, for men of 18-30 years old - (0.0630 × body weight, kg + 2.8957) × 240, of 31-60 years old - (0.0484 × body weight, kg + 3.6534) × 240; over 60 years old - (0.0491 × body weight, kg + 2.4587) × 240. The graduated physical exercises represent morning hygienic gymnastics, therapeutic exercises and graduated physical exercises throughout a day. The preparations pioglitazone 30 mg and amlodipine 10 mg are introduced once a day in the same time. The therapy is performed for 4 months.

EFFECT: method provides correction of reduced vascular wall function in the patients with degree I-II AH associating MS suffered eye vessel thrombosis for 4 months and allows avoiding vascular complications in such patients.

1 dwg, 1 tbl, 2 ex

FIELD: food industry.

SUBSTANCE: probiotic oligosaccharides mixture contains 5-70 wt % of at least one N-acetylated oligosaccharide chosen from the group containing GalNAcαl,3Galβ1,4Glc and Galβ1,6GalNAcα1,3Galβ1,4Glc, 20-90 wt.% of at least one neutral oligosaccharide chosen from the group containing Galβ1,6Gal, Galβ1,6Galβ1,4Glc, Galβ1,6Galβ1,6Glc, Galβ1,3Galα1,3Glc, Galβ1,3Galβ1,4Glc, Galβ1,6Galβ1,6Galβ1,4Glc, Galβ1,6Galβ1,3Galβ1,4Glc, Galβ1,3Galβ1,6Galβ1,4Glc and Galβ1,3Galβ1,3Galβ1,4Glc, and 5-50 wt % of at least one sialylated oligosaccharide chosen from the group containing NeuAcα2,3Galβ1,4Glc and NeuAcα2,6Galβ1,4Glc. The food product is represented by a mixture for infant feeding and is characterised by the fact that it contains the said oligosaccharide mixture.

EFFECT: invention ensures predominant effect of the probiotic oligosaccharide mixture on the balance of microbiota, improves state of the host health.

11 cl, 3 dwg, 4 ex

FIELD: food industry.

SUBSTANCE: invention relates to food industry. The method for production of flour confectionary products of preventive purpose involves dough preparation, moulding and baking dough semi-products. For the dough preparation one uses a preventive additive represented by arabinogalactan powder of Siberian and Gmelenii larch wood. The compositions of flour confectionary products of preventive purpose include prime grade bakery wheat flour, melange, sugar sand, treacle, margarine, starch, whole milk, culinary edible salt, carbon-ammonium salt, soda and vegetal raw material. The raw material is represented by the preventive additive i.e. arabinogalactan powder of Siberian and Gmelenii larch wood. The mixture components are taken at the specified ratio.

EFFECT: invention allows to produce products with preventive properties; the products have a high surface colour, a sweeter taste which allows to reduce sugar sand recipe quantity lowering the products calorie content.

4 cl, 6 dwg, 3 tbl, 22 ex

FIELD: medicine.

SUBSTANCE: composition for treating a HIV-infected patient contains eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and arachidonic acid (ARA), and at least two different oligosaccharides (OL1 and OL2) having monosaccharide unit homology 90 % and lower. In EPA, DHA and ARA, the long-chain polyunsaturated fatty acid content with 20 and 22 carbon atoms does not exceed 85 wt % of total fat content. The offered food composition contains EPA, DHA and ARA, at least two different oligosaccharides having monosaccharide unit homology 90 % and lower, and sour oligosaccharides, preferentially uronic acid polymer of degree of polymerisation 2 to 60. The food composition is also used for making a drug for diarrhoeia treatment or prevention in the HIV-infected patient.

EFFECT: barrier integrity improvement in HIV patients.

11 cl, 7 dwg, 4 tbl, 6 ex

FIELD: food industry.

SUBSTANCE: composition is extruded and represents chewing gum containing: a cellulose component represented by sugar-free inulin -25% - 75% of the said composition weight, a moistener component - 0.001% - 20% of the said composition weight, a carbohydrate component - 5% - 40% of the said composition weight, a fatty component - in an amount of less than 10% of the said composition weight.

EFFECT: composition possesses a pleasant taste, it is a low-caloric and suitable for the consumer, the composition ensures delivery of a high quantity of cellulose to the consumer.

26 cl, 2 tbl, 9 ex

FIELD: food industry.

SUBSTANCE: fermented food product based on linseed is produced by defatting linseed, its crushing and milling, blending crushed and milled linseed with water, probably with addition of other cereals or plant seeds or linseed fraction at a concentration of nearly 3 - nearly 8 wt % to produce a suspension. The suspension is fermented with a starter, i.e. Bifidobacterium lactis Bb12 strain, enriched and stabilised to produce a viscous or fermented drinkable snack product.

EFFECT: invention allows to produce a product enriched with probiotic bacteria and having low fat content.

15 cl, 15 tbl, 11 ex

FIELD: food industry.

SUBSTANCE: mixture for baby feeding contains a source of proteins based on milk whey, casein and their mixture as well as based on soya in an amount of no more than 2.0 g/100 kcal, a source of lipids, a source of carbohydrates and a probiotic or a mixture of probiotics. The probiotic or the mixture of probiotics is/are represented by strain(s) preferably chosen from Lactobacillus and/or Bifidobacterium genus in an amount equivalent to 102-105 CFU/g of the dry mixture. The source of lipids and carbohydrates is suitable for use in baby mixtures.

EFFECT: possibility for application of the mixture for newborn baby immune system modulation for initiation of development of useful digestive microbiota (in the initial few weeks of baby life) comparable to microbiota of babies fed with breast milk as well as for stimulation of maturation of newborn baby immune system in the initial few weeks of baby life.

12 cl, 1 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to cardiology and angiology, and can be used for correction of vessel wall dysfunctions in patients with arterial hypertension (AH) of III degree with metabolic syndrome (MS), who had eye vessel thrombosis. For this purpose, at the background of individually selected hypocaloric diet and dosed physical exercise medications pioglitazone, lisinopril and amlodipine are introduced. Hypocaloric diet is calculated in kcal by formula: for women of 18-30 years - (0.0621 × body weight, kg + 2.0357) × 240, 31-60 years - (0.342 × body weight, kg + 3.5377) × 240, over 60 years - (0.0377 × body weight, kg + 2.7545) × 240, for men of 18-30 years - (0.0630 × body weight, kg + 2.8957) × 240, 31-60 years - (0.0484 × body weight, kg + 3.6534) × 240; over 60 years - (0.0491 × body weight, kg +2.4587) × 240. Dosed physical exercise includes morning hygienic gymnastics, exercise therapy and dosed physical exercises during the day. Medication pioglitazone is introduced in dose 30 mg 1 time per day, lisinipril in dose 10 mg 1 time per day and amlodipine 10 mg 1 time per day at the same time of the day. Treatment is carried out for 4 months.

EFFECT: method ensures correction of attenuation of vessel wall functions in patients with AH of III degree with MS, after eye vessel thrombosis during 4 months and makes it possible to avoid vascular complications in such patients.

1 dwg, 1 tbl, 1 ex

FIELD: food-processing industry, in particular, production of gerodietary food.

SUBSTANCE: method involves preparing and mixing cabbage, tomato, onion, carrot and edible salt; packing resultant mixture; while mixing said components, additionally introducing fermentolysate of fish processing wastes and acidic hydrolisate of fish processing wastes, soya texturizer, flour of bean, sorghum groats, CO2-extract of dill and celery, rape-seed oil, and preparation produced from Mortierella lignicola microorganism biomass by sequential extraction with the use of non-polar extractant in above-critical state, water, alkaline, water, acid, water, alkaline, and water, with following joining of first extract with solid residue. Components are used in dried state and at predetermined ratio.

EFFECT: wider range of gerodietary products.

FIELD: food-processing industry.

SUBSTANCE: method involves mixing dried fermentolysate of fish farce, cabbage, tomato, flour of bean, onion, carrot, sorghum groats, edible salt, CO2-extracts of dill and celery, preparation produced from Mortierella dichotoma micromycet biomass by predetermined process, and rape-seed oil; packing mixture.

EFFECT: increased content of poly-unsaturated fatty acids, vitamins and nutritive substances in gerodietary product in accessible form.

FIELD: food-processing industry.

SUBSTANCE: method involves mixing dried fermentolysate and acidic hydrolisate of fish processing wastes, soya texturizer, cabbage, tomato, flour of bean, onion, carrot, sorghum groats, edible salt, CO2-extracts of dill and celery, rape-seed oil, and preparation produced from Mortierella parvispora microorganism biomass by predetermined process; packing mixture.

EFFECT: improved quality of gerodietary product and increased content of nutritive substances in easily assimilated form.

FIELD: food-processing industry.

SUBSTANCE: method involves mixing dried fermentolysate and acidic hydrolisate of fish processing wastes, soya texturizer, cabbage, tomato, flour of bean, onion, carrot, sorghum groats, edible salt, CO2-extracts of dill and celery, rape-seed oil, and preparation produced from Mortierella indohii microorganism biomass by predetermined process; packing mixture.

EFFECT: improved quality of gerodietary product and increased content of nutritive substances in easily assimilated form.

FIELD: food-processing industry.

SUBSTANCE: method involves mixing dried fermentolysate and acidic hydrolisate of fish processing wastes, soya texturizer, cabbage, tomato, flour of bean, onion, carrot, sorghum groats, edible salt, CO2-extracts of dill and celery, rape-seed oil, and preparation produced from Mortierella pulchella microorganism biomass by predetermined process; packing mixture.

EFFECT: improved quality of gerodietary product and increased content of nutritive substances in easily assimilated form.

FIELD: food-processing industry.

SUBSTANCE: method involves mixing dried fermentolysate and acidic hydrolisate of fish processing wastes, soya texturizer, cabbage, tomato, flour of bean, onion, carrot, sorghum groats, edible salt, CO2-extracts of dill and celery, rape-seed oil, and preparation produced from Mortierella globalpina microorganism biomass by predetermined process; packing mixture.

EFFECT: improved quality of gerodietary product and increased content of nutritive substances in easily assimilated form.

FIELD: biotechnology, food and medicinal industry, microbiology.

SUBSTANCE: the strain Bifidobacterium longum 379-IN is obtained by selection without using methods of genetic modification of the strain Bifidobacterium longum B379M and distinct by ability to utilize insulin. The strain is deposited in GKNM GU "MNIIEM named for G. N. Gabrichevskiy Russia Ministry of Public Health" at № 172. The strain shows high technological effectiveness, accumulates biomass with substrates of vegetable origin and artificial nutrient media for short periods with concentration of bifidobacteria, it elicits acid-forming and antagonistic properties with respect to pathogenic and putrid microflora. This allows its using in manufacturing bacterial preparations, biologically active supplements for food, fermented-dairy and nonfermented-dairy foodstuffs, ferments, hygienic and cosmetic agents providing probiotic effect and normalization of microbiocenosis in human body, among them in gastroenteric and urogenital tracts, cutaneous and mucosa integuments. Invention can be used in manufacturing bacterial preparations, biologically active supplements for food, fermented-dairy and nonfermented-dairy foodstuffs, hygienic and cosmetic agents.

EFFECT: valuable properties of strain, expanded assortment of similar agents.

6 ex

FIELD: food-processing industry.

SUBSTANCE: method involves mixing dried fermentolysate and dried acid hydrolysate of fish processing wastes, soya texturizer, cabbage, tomato, bean flour, onion, carrot, sorghum groats, edible salt, CO2-extracts of dill and celery, rape oil and preparation of Pythium coloratum microorganism biomass produced by predetermined process; packing resultant mixture.

EFFECT: provision for obtaining of gerodietary food product with increased content of phosphor, calcium and nutritive substances in accessible form.

FIELD: food-processing industry.

SUBSTANCE: method involves mixing dried fish farce, cabbage, tomato, bean flour, onion, carrot, sorghum groats, ground pike pyloric appendages, edible salt, CO2-extracts of dill and celery, rape oil and preparation produced from Mortierella alpina micromycet biomass by predetermined process; packing resultant mixture.

EFFECT: provision for obtaining of gerodietary food product with increased content of polyunsaturated fatty acids, vitamins, and nutritive substances in accessible form.

FIELD: food-processing industry.

SUBSTANCE: method involves preparing and mixing cabbage, tomato, onion, carrot and edible salt; while mixing, additionally introducing fermentolysate of fish processing wastes, acid hydrolysate of fish processing wastes, soya texturizer, bean flour, sorghum groats, CO2-extract of dill and celery, rape-seed oil and specific preparation; packing resultant mixture. Specific preparation is produced from Mortierella gamsii micromycet biomass by sequentially extracting thereof with the use of non-polar extractant in above-critical state, water, alkaline, water, acid, water, alkaline, and water, with following joining of first extract with solid residue. Components are used in dried state and are added in predetermined amounts.

EFFECT: wider range of gerodietary products.

Up!